Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.

Barban V, Mantel N, De Montfort A, Pagnon A, Pradezynski F, Lang J, Boudet F.

J Virol. 2018 May 29;92(12). pii: e00440-18. doi: 10.1128/JVI.00440-18. Print 2018 Jun 15.

2.

Replacement of primary monkey kidney cells by L20B cell line in the test for effective inactivation of inactivated poliovirus vaccine.

Chapel C, Rocher-Hélion N, Mantel N, Imbert S, Deshaies E, Barban V, Sabouraud A, Barbe JP, Mallet L.

J Virol Methods. 2018 Jun;256:77-84. doi: 10.1016/j.jviromet.2018.03.004. Epub 2018 Mar 13.

3.

Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.

Bernard MC, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, Londono-Hayes P.

PLoS One. 2015 Apr 2;10(4):e0121518. doi: 10.1371/journal.pone.0121518. eCollection 2015.

4.

Yellow fever vaccine: comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain.

Moulin JC, Silvano J, Barban V, Riou P, Allain C.

Biologicals. 2013 Jul;41(4):238-46. doi: 10.1016/j.biologicals.2013.04.005. Epub 2013 Jun 10.

PMID:
23763825
5.

Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks.

Kazimírová M, Mantel N, Raynaud S, Slovák M, Ustaniková K, Lang J, Guy B, Barban V, Labuda M.

Vector Borne Zoonotic Dis. 2012 Nov;12(11):979-85. doi: 10.1089/vbz.2011.0947. Epub 2012 Aug 27.

PMID:
22925017
6.

Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.

Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude JB, Lang J.

Virology. 2012 Aug 1;429(2):91-8. doi: 10.1016/j.virol.2012.03.007. Epub 2012 Apr 25.

7.

Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses.

Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, Barban V.

Vaccine. 2011 Sep 2;29(38):6629-35. doi: 10.1016/j.vaccine.2011.06.101. Epub 2011 Jul 13.

PMID:
21745519
8.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
9.

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J.

Am J Trop Med Hyg. 2009 Feb;80(2):302-11.

PMID:
19190230
10.

Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines.

Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, Barban V.

J Virol Methods. 2008 Jul;151(1):40-6. doi: 10.1016/j.jviromet.2008.03.026. Epub 2008 May 22.

PMID:
18501437
11.
12.

High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

Barban V, Girerd Y, Aguirre M, Gulia S, Pétiard F, Riou P, Barrere B, Lang J.

Vaccine. 2007 Apr 12;25(15):2941-50. Epub 2006 Aug 1.

PMID:
16914238
13.

Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient.

Barban V, Fraysse-Corgier S, Paranhos-Baccala G, Petit M, Manin C, Berard Y, Prince AM, Mandrand B, Meulien P.

J Gen Virol. 2000 Feb;81(Pt 2):461-9.

PMID:
10644845
14.

Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo.

Levrero M, Barban V, Manteca S, Ballay A, Balsamo C, Avantaggiati ML, Natoli G, Skellekens H, Tiollais P, Perricaudet M.

Gene. 1991 May 30;101(2):195-202.

PMID:
1829048
15.

Transcription of visna virus during its lytic cycle: evidence for a sequential early and late gene expression.

Vigne R, Barban V, Quérat G, Mazarin V, Gourdou I, Sauze N.

Virology. 1987 Nov;161(1):218-27.

PMID:
2823463
16.

Characteristics of a novel lentivirus derived from South African sheep with pulmonary adenocarcinoma (jaagsiekte).

Quérat G, Barban V, Sauze N, Vigne R, Payne A, York D, De Villiers EM, Verwoerd DW.

Virology. 1987 May;158(1):158-67.

PMID:
2437695
17.

Isolation and identification of a South African lentivirus from jaagsiekte lungs.

Payne A, York DF, de Villiers EM, Verwoerd DW, Quérat G, Barban V, Sauze N, Vigne R.

Onderstepoort J Vet Res. 1986 Mar;53(1):55-62.

PMID:
3008059
18.

Lentiviruses are naturally resident in a latent form in long-term ovine fibroblast cultures.

Barban V, Quérat G, Sauze N, Filippi P, Vigne R, Russo P, Vitu C.

J Virol. 1984 Nov;52(2):680-2.

19.

Highly lytic and persistent lentiviruses naturally present in sheep with progressive pneumonia are genetically distinct.

Quérat G, Barban V, Sauze N, Filippi P, Vigne R, Russo P, Vitu C.

J Virol. 1984 Nov;52(2):672-9.

Supplemental Content

Loading ...
Support Center